Ramipril

Ramipril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for ramipril capsules (a generic product), lists three uses: treating high blood pressure, reducing the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years or older who are at high risk, and treating stable patients who show clinical signs of congestive heart failure after a myocardial infarction. The label read is a generic product label; the brand names for this substance are recorded as aliases.

Also called Altace

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 35296; UNII L35JN3I7SJ. UNII L35JN3I7SJ is the UNII of the substance as the label names it. MeSH descriptor D017257 is Ramipril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Lupin Pharmaceuticals, Inc. label for ramipril capsules, application ANDA077626, effective 2026-08-24 in openFDA; Drugs@FDA lists the application's sponsor as LUPIN. The brand label for Altace (NDA019901, listed as discontinued in Drugs@FDA) and other generic ramipril labels were not used. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 5 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
5
Phase 3 or 4
4
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedUnknown statusAll statuses
Phase 20101
Phase 31113
Phase 40101
All phases1315

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The cardiovascular risk reduction indication names patients 55 years or older at high risk; the other indications do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
55 years or older for the risk reduction indication, as the passage read states; not stated for the other indications
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ramipril capsules, in the Lupin Pharmaceuticals, Inc. version dated 2026-08-24 in openFDA (a generic product), lists the medicine for the treatment of hypertension; in patients 55 years or older at high risk of developing a major cardiovascular event, to reduce the risk of heart attack (myocardial infarction), stroke or cardiovascular death; and in stable patients with clinical signs of congestive heart failure after a myocardial infarction.

    Applies to Recipient not specified Patients for whom the US label of ramipril capsules lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk, heart failure after myocardial infarction

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for ramipril capsules, Lupin Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a8cdec12-81d1-4ef4-82c0-d05d93c37a07 (manufacturer Lupin Pharmaceuticals, Inc., application ANDA077626), returned on 2026-11-09. The label text is dated 2026-08-24 (effective_time). Other openFDA records of ramipril labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-08-24
      Source state
      Current
      Version fingerprint
      24f903fd224e0ef770232bcf983d79d62f096b11a99cc6e76477543c06681017
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ramipril capsules, Lupin Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a8cdec12-81d1-4ef4-82c0-d05d93c37a07 (manufacturer Lupin Pharmaceuticals, Inc., application ANDA077626), returned on 2026-11-09. The label text is dated 2026-08-24 (effective_time). Other openFDA records of ramipril labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260824.
      Retrieved
      Source effective date
      2026-08-24
      Source state
      Current
      Version fingerprint
      24f903fd224e0ef770232bcf983d79d62f096b11a99cc6e76477543c06681017
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application ANDA077626 (RAMIPRIL, sponsor LUPIN): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application ANDA077626, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application ANDA077626, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      bf76a68dfcbe9d23ddaf931da089463694952084b2de52dda2c12a03a9db90a6
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ALTACE

No label from the application holder was found in the openFDA label dataset for application NDA019901. This page does not show another labeler's label in its place.

ALTACE

No label from the application holder was found in the openFDA label dataset for application NDA022021. This page does not show another labeler's label in its place.

VOSTALLY

No label from the application holder was found in the openFDA label dataset for application NDA219757. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019901 ALTACE
  2. Supplemental approval NDA019901 ALTACE
  3. Supplemental approval NDA019901 ALTACE
  4. Approval NDA022021 ALTACE
  5. Approval NDA219757 VOSTALLY

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 3

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA019901

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022021

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA219757

Record details

Record id
cardio:ramipril
Content hash
4fb1c6ce9447bbdd019c85d09958e6144a3916bcdda695d580320c32966ae7f7